the NWCS319 and ACTG 5175 study team Introduction: Numerous micronutrients have immunomodulatory roles that may influence risk of tuberculosis (TB), but the association between baseline micronutrient deficiencies and incident TB after antiretroviral therapy (ART) initiation in HIV-infected individuals is not well characterized.
INTRODUCTION
Tuberculosis (TB) is the leading single-agent infectious cause of death worldwide, killing an estimated 1.5 million people in 2014. 1 It is also one of the primary causes of early mortality in patients starting antiretroviral therapy (ART) in low-and middle-income countries (LMICs). 2, 3 Micronutrient deficiencies are common in people living with HIV, particularly in LMIC. A lack of availability of micronutrient-rich foods, reduced dietary intake because of advanced HIV, excessive gastrointestinal losses from diarrhea and malabsorption, and chronic inflammation affect the overall nutrition of HIV-infected individuals. Nonspecific markers of nutritional status, including low body mass index (BMI), low albumin, and anemia (both iron-deficiency and anemia of chronic disease) are associated with increased TB risk after ART initiation. [4] [5] [6] [7] [8] [9] [10] [11] However, these general markers are incompletely predictive of TB; in particular, the role of deficiencies in individual micronutrients with immunomodulatory properties on susceptibility to new or reactivation TB is poorly understood. There is a need to accurately establish TB risk associated with individual micronutrient deficiencies. Because patients in LMIC who survive the early months of ART experience high levels of subsequent survival, 12, 13 finding modifiable nutritional risk factors could also lead to targeted interventions aimed at reducing TB incidence and mortality during the critical early treatment period.
Several micronutrients play plausible roles in TB immunopathogenesis. [14] [15] [16] Animal models highlight a plausible role of deficiencies and TB risk and clinical outcomes. 17, 18 Furthermore, decreased levels of multiple micronutrients, including vitamins A, [19] [20] [21] carotenoids 22 ; vitamin D, [23] [24] [25] [26] [27] [28] [29] vitamin E, [30] [31] [32] and selenium, [32] [33] [34] [35] [36] are frequently observed in patients with TB and often correlate with severity of disease. However, previous studies have mostly been cross-sectional, focused on single micronutrients, or supplementation trials including patients with prevalent TB, and most did not adjust other important variables including BMI or inflammatory markers.
In this study, we sought to assess multiple micronutrients at baseline before initiation of ART and look longitudinally at the outcome of incident TB in a diverse population from 9 predominantly high-HIV, high-TB, LMIC settings.
METHODS

Study Participants
Our study population was sampled from the Prospective Evaluation of Antiretrovirals in Resource Limited Settings (PEARLS) trial [Adult AIDS Clinical Trials Group (ACTG) A5175, clinicaltrials.gov NCT00084136], an open-label randomized trial evaluating the noninferiority of once-daily versus twice-daily dosing of 3 ART regimens. The parent study is described in detail elsewhere. 37 In brief, between May 2005 and July 2007, 1571 treatment-naive HIV-1-infected adults with CD4 + T-cell counts ,300 cells/mm 3 from 9 countries, including Brazil (n = 231), Haiti (n = 100), India (n = 255), Malawi (n = 221), Peru (n = 134), South Africa (n = 210), Thailand (n = 100), the United States (n = 210), and Zimbabwe (n = 110), were randomized to 1 of 3 ART treatment arms. Inclusion requirements included age $18 years, CD4 + T-cell count ,300 cells/mm 3 , 7 days or less of cumulative ART use, negative pregnancy test and absence of significant derangement in baseline laboratory values (including haemoglobin ,7.5 g/dL, estimated creatinine clearance ,60 mL/min, aspartate aminotransferase or alanine aminotransferase .5 times upper limit of normal), all documented within 45 days of study entry. Participants with prevalent TB at study entry were excluded for our analysis, and patients with serious acute, chronic, or recurrent infections must have been clinically stable and completed at least 14 days of appropriate therapy.
We performed a case-cohort design to evaluate the association between micronutrient deficiencies and incident TB to allow efficient assessment of outcomes and as this design provides similar effect estimates and standard errors compared with full cohorts with cohorts of .1250 participants and sampling fraction .10%. [38] [39] [40] Cases were defined as participants diagnosed with incident TB within 96 weeks after ART initiation. Two hundred seventy randomly selected participants (30 per country, 10 per ART treatment arm) from the parent study and additional TB cases not in the random subcohort made up a full case-cohort sample of 332 participants used for this analysis. TB cases included 15 in the random subcohort and 62 not in the random subcohort (77 total). The study population is described in Figure 1 and Table 1 .
Study approval was obtained from the institutional review board and ethics committee at the Johns Hopkins University (JHU) and at each participating institution. Written informed consent was obtained from all participants.
Data Collection and Laboratory Assessment
Along with a detailed history and physical examination of the participants, a complete blood count (CBC), and HIV RNA viral load were obtained before initiating ART. CD4 count was obtained 7-45 days before initiation of ART. HIV RNA levels were measured by real-time polymerase chain reaction by the Amplicor HIV-1 Monitor Test, v1.5 (Roche, Branchburg, NJ). Both the HIV RNA testing and CD4 count were done at externally quality-assured laboratories. History and physical examinations were performed routinely at scheduled visits on weeks 2, 4, 8, then every 4 weeks through week 24, and then every 8 weeks through week 96. Incident TB was diagnosed according to standard ACTG definitions described elsewhere (Appendix 60, Ref. 37).
Micronutrient Selection and Measurement
Micronutrients with a suspected or proven role in the pathogenesis of TB were selected for measurement and analysis. We did not include iron status or hypoalbuminemia as exposures of interest in this analysis as we have previously published on anemia, iron status, inflammation, and risk of TB. 11, 41 Micronutrient concentrations for study participants were measured using archived plasma or serum that had been collected within 14 days of starting ART (pre-ART) and stored at 280°C at laboratories certified by National Institute of Health (NIH) Division of AIDS using standardized protocols.
To minimize variation in measurements, all micronutrients were measured at a single laboratory at Johns Hopkins University that had extensive experience with micronutrient assays. Total (vitamin D2 and D3) serum 25-hydroxyvitamin D was measured using DiaSorin (Stillwater, MN). Serum vitamin B12 concentration was measured using Abbott AxSYM (Abbott Laboratories), an immunochemical automated analyzer, and serum vitamin B6 using highperformance liquid chromatography (HPLC) with florescence detection. HPLC-ultraviolet was used to measure serum concentrations of retinol (vitamin A); the following carotenoids (a-carotene, b-carotene, b-cryptoxanthin, lutein, zeaxanthin, and lycopene), and vitamin E (a and g-tocopherol). A Perkins-Elmer AAnalyst 600 graphite furnace atomic absorption spectrometer was used to measure serum selenium concentrations. To adjust relevant micronutrient levels for inflammation status, we also measured C-reactive protein (CRP) using enzyme-linked immunosorbent assay kits by R & D Systems at JHU. 11 External quality assurance for the laboratory measurements was taken as per the NIH Division of AIDS and AIDS Clinical Trials Group (ACTG) Network laboratory quality Assurance guidelines. 37 
Statistical Analyses
We used cutoff values for micronutrient deficiency based on previous studies: ,1.05 mmol/L or ,0.7 mmol/L for vitamin A as different definitions have been proposed; ,19 nmol/L for vitamin B6; ,148 pmol/L for vitamin B12; ,20 ng/mL for vitamin D (25-hydroxyvitamin D); ,9.3 mmol/L for a-tocopherol (vitamin E isoform); and ,85 mg/L for selenium. [42] [43] [44] [45] We also included vitamin D insufficiency (20 to ,32 ng/mL). No widely accepted cutoff values exist for deficiencies in g-tocopherol (vitamin E isoform) or carotenoids (a-carotene, b-carotene, b-cryptoxanthin, lutein, zeaxanthin, and lycopene). We therefore measured total carotenoids by summing individual measurements and compared patients above or below the median total concentration, as well as above or below median g-tocopherol levels to evaluate the association between relative deficiency and risk ‡EFV+3 TC/ZDV = efavirenz 600 mg daily, lamivudine/zidovudine 150 mg/300 mg twice daily.
IQR, interquartile range.
of TB. Only 1 patient met the criteria for a-tocopherol (vitamin E isoform) deficiency (,9.3 mmol/L) so we also compared groups above or below median concentration for risk of incident TB. The primary objective in our analyses was to assess baseline micronutrient levels in a case-cohort sample and determine the relationship between baseline deficiencies and incident TB within 96 weeks of starting ART. Baseline characteristics of cases and noncases were compared using the nonparametric Mann-Whitney U test for continuous variables or Fisher's exact test for discrete variables. Medians and interquartile ranges were shown for continuous data and proportions for discrete data. History of TB was obtained by self-report. Univariate and multivariable Cox regression analyses were used to ascertain associations between baseline (pre-ART) micronutrient deficiencies and incident TB post-ART initiation using stratified Breslow weights (stratified by country of origin and treatment arm). In our primary analysis, we included all variables thought to have a potential a priori association with incident TB, plus each micronutrient separately. To confirm that our results did not reflect model overfitting, we added variables to the model one at a time and checked hazards ratios for micronutrient deficiencies at each step. The primary multivariable model adjusted for age, sex, treatment arm, country of origin, history of TB, baseline CD4 count (cells/mm 3 ), baseline HIV log 10 viral load, BMI, and baseline CRP (which has been shown to influence measured serum concentrations of several micronutrients). [46] [47] [48] Age, CD4 count, viral load, BMI, and CRP were analyzed as continuous variables. In secondary, post hoc analysis, we also adjusted for other micronutrient deficiencies found to have a statistically significant association with incident TB. Furthermore, as serum vitamin A can decrease during an acute phase response, we performed a secondary analysis restricted to cases diagnosed after 1 month. Kaplan-Meier estimates were used to calculate time to incident TB among the patients for selected micronutrients that either had an independent association or have been shown in our previous studies to be associated with TB. The log-rank test was used to evaluate univariate differences in groups for time to incident TB. Data were analyzed using S-Plus version 8.
RESULTS
Study Population Characteristics
A total of 77 incident TB cases were identified in the PEARLS trials by 96 weeks after ART initiation (Fig. 1) . These included 55 pulmonary and 22 extrapulmonary TB cases. Pooled median pretreatment CD4 + T-cell count was 170 cells/mm 3 47 .3% of patients were female, and 53.6% black. Among the 77 cases and 255 noncases in the casecohort sample, there were no significant differences in median age, sex, or treatment arm assignment (Table 1) . Compared with noncases, cases had lower median CD4 count (136 vs. 180 cells/mm 3 , P = 0.002), a trend toward higher median log 10 HIV viral load (5.2 vs. 5.0, P = 0.07), higher probability of previous TB (32% vs. 17%, P = 0.006), and higher baseline prevalence of both anemia and hypoalbuminemia, as previously described. 41 Cases and noncases differed significantly with respect to study site/country of origin (P , 0.001), with about 3-quarters of TB cases from India (28.5% of total cases), Malawi (18.2%), or South Africa (27.3%). Among TB cases, the median time to diagnosis was 24 weeks; those who initiated ART at a lower CD4 cell count (,200 cells/mm 3 ) had a shorter time to diagnosis (P = 0.01) as compared with those with high baseline CD4 cell count ($200 cells/mm 3 ).
Micronutrient Status Pre-ART and Incident TB
With regard to micronutrient status at ART initiation, cases had significantly lower baseline median levels of g-tocopherol (2.18 vs. 2.67 mmol/L, P = 0.01), total carotenoids (0.83 vs. 1.10 mmol/L, P , 0.001) and selenium (62.74 vs. 84.25 mmol/L, P , 0.001) than noncases ( Table 2 ). Vitamin A (1.35 vs. 1.53 mmol/L, P = 0.07) and vitamin D (30 vs. 32 ng/mL, P = 0.07) levels were marginally lower among cases. The median values of other micronutrients did not differ significantly between groups. Using established deficiency cutoffs, 7% of cases and 3% of noncases were deficient in vitamin A (,0.7 mmol/L), 31% and 37% in vitamin B6 (,19 nmol/L), 6% and 9% in vitamin B12 (,148 pmol/L), 22% and 14% in vitamin D (,20 ng/mL), 2% and 0% in a-tocopherol (vitamin E isoform) (,9.3 mmol/L), and 76% and 51% in selenium (,85 mg/L). Baseline micronutrient deficiency prevalence in the subcohort was previously described. 49 Deficiencies in serum vitamin A, vitamin D, and selenium were associated with increased hazards of incident TB in univariate analysis. After adjusting for potential confounders, pre-ART deficiencies of vitamin A (,0.7 (Fig. 2) .
DISCUSSION
In this case-cohort study of adults with advanced HIV Infection in 9 mostly high-burden TB countries, individuals who developed TB after ART initiation were more likely to have pretreatment deficiency in vitamin A and vitamin D than randomly selected patients who did not develop TB (ie, noncases) during follow-up. Deficiencies in vitamins A and D were each associated with more than tripling of the hazard of incident TB after ART initiation. Both associations remained significant after adjusting for BMI, inflammatory status, and other potential confounders. These findings provide new insight into micronutrient status and incident TB in a diverse multinational population initiating ART.
Micronutrient deficiencies are common in individuals with prevalent TB, with or without concomitant HIV infection. A number of supplementation trials have examined the effect of adjunctive micronutrients with standard chemotherapy on TB outcomes (reviewed in Ref. 50 ), but few have assessed risk of development of TB in the era of ART. Notably, the potential immunologic role of micronutrients in 51 These previous trials had significant heterogeneity in patient populations, including proportion of HIV-infected patients and age categories, composition of multivitamin supplements, outcomes measured, and length of follow-up, limiting conclusions and generalizability of findings. Although many of these studies failed to find an additive clinical benefit of adjunctive micronutrient supplementation, 50 a large doubleblinded, randomized-controlled trial of 887 patients with pulmonary TB in Tanzania found a 45% reduction in TB recurrence in patients who received multivitamin supplementation (which included vitamins A, B complex, C, E, and selenium) compared with the placebo arm over a median follow-up period of 43 months, with an even greater reduction (63%) observed in HIV-infected patients. 52 This finding is both clinically relevant given high rates of TB recurrence observed in resource-limited settings (32% of patients with incident TB in our cohort had a history of TB) [53] [54] [55] and because it suggests a potential protective role in TB of one or several micronutrients. Vitamin D deficiency is frequently observed in individuals with TB, with additional data from (mostly HIVuninfected) cohort studies suggesting an association between deficiency and risk of downstream disease. 23, 25, 27, [56] [57] [58] [59] Immunologically, vitamin D modulates both the innate and adaptive immune response-it promotes downregulation of Th1 immune responses but also toll-like receptor-mediated macrophage activation, cathelicidin-dependent phagosome maturation and fusion with lysosomes, and intracellular killing of Mycobacterium tuberculosis. 16, [60] [61] [62] Vitamin D insufficiency (defined as ,30 ng/mL) was associated with a 66% (95% CI: 4% to 164%) higher rate of relapse, defined in this study as MTB culture-positivity in culture-negative patients at 1 month of antituberculous therapy, in the above Tanzanian supplementation trial cohort. 63 In a separate Tanzanian cohort of HIV-infected adults initiation ART, Sudfeld et al 57 observed that baseline 25-hydroxyvitamin D deficiency (,20 ng/mL), but not insufficiency (defined as 20-30 ng/mL), was associated with increased risk of incident pulmonary TB after ART initiation, adjusting for age, sex, ART regimen, BMI, and CD4 + T-cell count, season, and World Health Organization HIV disease stage (aHR 2.89, P = 0.027) with a median follow-up of 20.6 months and 43 TB cases. Using similar a priori adjustment variables, we found a comparable relative increase in hazard of early TB after ART initiation for patients with baseline vitamin D deficiency (aHR 3.66, 95% CI: 1.16 to 11.51). Our study provides further support that vitamin D is a significant predictor of TB post-ART and has additional strengths, including a larger TB case number, use of a diverse, multinational patient population, evaluation of multiple micronutrient deficiencies, adjustment for inflammation (which affects serum micronutrient assessment), and rigorous patient follow-up and clinical assessment as a subanalysis within an ACTG study.
Vitamin A deficiency is commonly observed in individuals with prevalent TB and is associated with disease severity, but data from cohort studies evaluating vitamin A deficiency state and risk of downstream TB in high-TB, high-HIV settings are limited. 10, [19] [20] [21] In vitro studies have demonstrated an ability of vitamin A to inhibit M. tuberculosis replication in culture and within macrophages. [64] [65] [66] Vitamin A active metabolite [all-trans retinoic acid (ATRA)]-mediated reduction in the cellular cholesterol concentration and increased lysosomal acidification has been proposed as a possible mechanism for vitamin A enhancement of M. tuberculosis killing in infected macrophages. 14 Our exploratory findings suggest a potential preventive role of vitamin A for development of TB in high-risk patient populations.
Regarding other measured micronutrients, a previous study of HIV-infected injection drug users in the United States found a 3-fold risk of mycobacterial disease (75% M. tuberculosis) for more than 2 years in patients with baseline deficiency in selenium (defined as ,135 mg/L) after adjusting for ART use and CD4 + T-cell count, 36 but this study did not adjust for BMI or inflammatory status (which decreases measured selenium concentrations). 47 Although we found an association between baseline selenium deficiency (,85 mg/L) and risk of TB in univariate analysis, no association was found in our adjusted analysis. Other measured antioxidant micronutrients, including B vitamins, carotenoids, and vitamin E, have established roles in innate and adaptive immunity, 15 but we also failed to find an association between deficiency or relative deficiency and increased risk of TB. The reason for the inverse association between lower-than-median concentrations of g-tocopherol and TB is unclear.
Our study has some important limitations. First, the number of TB cases may have been too small to sufficiently detect differences in micronutrients that have a weaker association with TB risk. Although it helped in eliminating reverse causation, for improved generalizability, studies with larger sample size may be needed. Our patient population was also relatively healthy before starting ART, without premorbid AIDS-defining conditions, severe anemia, or other significant laboratory derangement, potentially diminishing strength of association between micronutrient deficiencies and TB and generalizability of study findings. Second, some of the micronutrients analyzed do not have established cutoffs for deficiency (namely carotenoids and g-tocopherol), and we therefore analyzed those patients for relative deficiency as a crude measure of association. Third, the study was not powered to test for interaction among the micronutrients. Fourth, certain micronutrients with limited circulating halflives are more prone to intraindividual variability of serum concentration, 67, 68 potentially attenuating the observed association between micronutrient status and TB risk. However, serial pre-ART blood collection to account for such variability was not feasible in this study. We also did not capture patient smoking status, which could influence micronutrient concentrations and TB risk. Last, this was an observational study intended to understand the role of micronutrients in increasing TB risk and not to identify or predict high-risk patients. However, with the identification of specific micronutrients and their role in subsequent TB status, this hypothesis-generating study provides additional insights into the potential role of vitamin D and vitamin A micronutrient supplementation and risk of developing TB among HIVinfected patients in resource-limited high-TB-burden settings. Several trials are now underway to assess the role of vitamin D supplementation and the risk of TB infection and disease in HIV-infected and uninfected individuals (NCT02880982, NCT01798680) and should shed light on vitamin D's role as a preventive therapy for acquisition of TB infection and risk of TB and TB/HIV progression. 69, 70 
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